Form 4: MariMed Inc. Insider Trades: Jon R. Levine Buys Shares

MariMed Inc. President and CEO Jon R. Levine reported a transaction involving the purchase of 40,000 common shares.

Summary

• Jon R. Levine, President and CEO of MariMed Inc., acquired 40,000 shares of common stock on May 20, 2026, at a price of $0.075 per share.
• Following this transaction, Levine directly beneficially owns 21,247,986 shares.
• An additional 6,684,640 shares are held indirectly through the Jon Levine Family Trust, for which Levine disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing due to the insider purchase, but the extremely low transaction price tempers enthusiasm and suggests potential underlying issues not detailed in the filing.

Positives

• Insider purchase of company stock by a key executive (President and CEO).
• Acquisition of a significant number of shares (40,000) by the CEO.

Negatives

• The purchase price of $0.075 per share indicates a very low valuation of the company's stock at the time of the transaction.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The low purchase price could reflect underlying concerns about the company's financial health or future prospects, though this is not stated.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Jon R. Levine disclaims beneficial ownership of shares held in the Jon Levine Family Trust, stating that the filing is not an admission of beneficial ownership for Section 16 or any other purpose.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a CEO, can signal confidence in the company's future. However, the very low purchase price warrants further investigation into the company's valuation and market conditions.

Related Party Transactions

• The filing notes shares held by the Jon Levine Family Trust, for which Jon R. Levine is the reporting person. He disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal of confidence, though the low price might raise questions about the company's current valuation.
• Employees may interpret the purchase as a sign of leadership belief in the company's stability and future.
• Creditors and suppliers are not directly impacted by this insider stock transaction.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Recommendation

The purchase by the CEO is a positive signal, but the extremely low price of the transaction suggests caution. Without more context on the company's financial health and strategic direction, a 'hold' recommendation is prudent, advising investors to monitor further disclosures.

Keywords

MariMed Inc., MRMD, Form 4, Insider Trading, Jon R. Levine, Stock Purchase, Beneficial Ownership, SEC Filing